

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Group 1621

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/SK/	AA	5,559,111	9/24/96	Göschke et al.	514	227	4/4/95
/SK/	AB	5,606,078	2/25/97	Göschke et al.	549	321	4/4/95
/SK/	AC	5,627,182	5/6/97	Göschke et al.	514	237	7/25/96
/SK/	AD	5,646,143	7/8/97	Göschke et al.	514	233	7/25/96
/SK/	AE	5,705,658	1/6/98	Göschke et al.	549	321	2/14/97
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
/SK/	AM	WO 02/40007 A	5/23/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
/SK/	AN	WO 03/103653 A	12/18/03	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/SK/	AR	Wood et al. Biochemical and Biophysical Research Communications 308, pp. 698-705, "Structure-based design of aliskiren, a novel orally effective rennin inhibitor. (2003)
/SK/	AS	Goeschke et al. Bioorganic & Medicinal Chemistry Letters, Vol. 7, No. 21, pp 2735-2740, Design and Synthesis of Novel 2,7-Dialkyl, Substituted 5(S)-Amino-4(S)-Hydroxy-8-Phenyl-Octanecarboxamides as <i>in Vitro</i> Potent Peptidomimetic inhibitors of Human Renin
	AT	

EXAMINER /Shailendra Kumar/ DATE CONSIDERED 10/27/2008

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.